Welcome to our dedicated page for AGE news (Ticker: AGE), a resource for investors and traders seeking the latest updates and insights on AGE stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AGE's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AGE's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
AgeX Therapeutics (NYSE American: AGE) announced it received a Deficiency Letter from the NYSE American on
AgeX Therapeutics, Inc. (AGE) reported its Q4 and full-year 2022 financial results, noting significant revenue decline. Q4 2022 revenues were $8,000, down from $27,000 in Q4 2021, while total annual revenues fell to $34,000 from $144,000 in 2021. Operating expenses for 2022 decreased to $7.0 million from $8.2 million in 2021. The net loss attributable to AgeX increased to $10.5 million, or ($0.28) per share, up from $8.7 million in 2021. The company raised doubts regarding its ability to continue as a going concern due to insufficient cash flows, with cash and equivalents at $0.7 million as of December 31, 2022 and a debt owed to Juvenescence of $21.4 million.